INTERIM REPORT JANUARY – MARCH 2017
FIRST QUARTER · Net sales amounted to MSEK 139.3 (82.3), equivalent to an increase of 69.3%. Growth was mainly due to acquisitions. · EBITDA amounted to MSEK 43.7 (9.3), which corresponds to a margin of 31.4% (11.3%) · Cash flow from operating activities amounted to MSEK 34.9 (-61.0) · Earnings per share was SEK 0.29 (0.05) · Cash and cash equivalents and other short-term investments at the end of the period amounted to MSEK 166.1 (11.2) · A rights issue raised a total of MSEK 374 SIGNIFICANT EVENTS AFTER PERIOD END · Pfizer pays a milestone of MUSD 2 ·